A new alkylating agent, Azetepa, is described. Our clinical experience in I25
patients with a variety of solid tumors is presented. Azetepa is useful chiefly in the
treatment of lymphomas, mammary carcinoma, and carcinomas of the female genital tract. Its efectiveness in carcinomas of the digestive tract and accessory organs is comparable to that of the fluorinated pyrimidines. It can be administered via all conventional routes. Toxicity was very low; no deaths due to hematologic causes occurred. There was no hepato-renal toxicity. Tentative recommendations are made for dosages and routes of administration.
Azetepa is a new alkylating agent with the structural formula : P, P-bis-(1 -aziridinyl)-Nethyl-N-( 1,3,4,-thiadiazol-2-yI)-phosphinic amide.
It incorporates within one molecule two reactive groups, a thiadiazol and a phosphoramide.
Comparison with Thio-Tepa in mice bearing 72j mammary adenocarcinoma revealed a higher carcinostatic index (Sloboda and Vogel, 1962).
The following is a report of our clinical experience with this agent, given through various routes to 125 patients with a variety of solid tumors, and incorporates the preliminary data of a previous report by one of the authors (Choy and Stylianou, 1962). Clinical efficacy has also been reported by other workers (Bateman, 1964;Falkson and Falkson, 1964).
MATERIAL AND METHODS